InnoMagic Bio Announces Completion of Angel+ Financing to Advance AI-Driven Proteomics Platform and Best-in-Class ADC Pipeline

Recently,Innovmab TherapeuticsCompleted the investment in Innovmab TherapeuticsAngel+ RoundFinancing.

This round of financing will be used to deeply integrate the proteomics technology platform with drug development, creating multiple ADC pipelines with best-in-class potential.

Innovmab Therapeutics is a company driven by omics big data to develop targeted drugs and novel precision medicine decision-making tools.

The company has established a unique drug R&D decision-making tool platform based on proteomics technology and a variety of highly clinically relevant disease model libraries such as PDX/PDO. By utilizing big data with high clinical relevance and deep biological knowledge obtained through AI computation, the platform promotes the high success rate development of self-developed new drug pipelines and IVD products.

In drug development,The company currently has multiple preclinical ADC new drug pipelines., including unique target products based on more than 10 years of academic accumulation, which can be developed into first-in-class products, giving the company a differentiated competitive advantage.

Innovmab Therapeutics will leverage its organoid multi-omics platform to achieve efficient and high-success-rate development of this ADC drug, while simultaneously advancing the development of combination therapies based on this product. Combination therapy is one of the most important developmental directions for ADC drugs. Through combination treatments, the effective dose of ADC can be significantly reduced, side effects minimized, and the therapeutic window expanded.

This technology platform will also be applied to the development of precision diagnosis and treatment biomarkers for diseases. Complex diseases such as cancer are often caused by multi-gene abnormalities and exhibit high heterogeneity, making biomarkers play a crucial role in the medical decision-making process.

However, there is still a serious lack of precise biomarkers available for clinical use. The main reasons for the difficulty in developing effective biomarkers include the lack of drug efficacy-related clinical models, lack of systematic efficacy data support, and low result comparability due to the lack of standardized high-quality data, among others.

In response to this significant unmet clinical need,Innovmab Therapeutics' Organoid Multi-Omics Platform Establishes Relationship Between Drug Efficacy and Multi-Omics Data Through AI Algorithms`, which can screen more precise combinations of pharmacodynamic markers, providing clinicians with accurate medication decision-making basis.`

Its core LDT product under development can simultaneously detect the activity of eight efficacy-related protein factors, providing guidance for targeted drug use based on the HER signaling pathway. It covers various indications such as breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, ovarian cancer, and melanoma. This product can be developed into a multi-target detection IVD kit for tumor pathology slides with a completely new concept.

In terms of technology output and cooperation, the company can leverage its organoid omics technology platform to provide a series of high-value R&D enabling services for medical testing institutions, pharmaceutical companies, and biotech enterprises, including screening of clinical diagnostic markers, co-development of novel LDT and IVD products, optimal indication assessment, drug repositioning, and more.

The company has utilized its proteomics technology to provide technical services for multiple enterprises and research institutions both in China and abroad, including collaborative research with Novartis Pharmaceuticals (USA) on two HER pathway-targeted drugs. Relevant articles will be published in international core journals.

Innovmab TherapeuticsFounder and CEO, Dr. Yong ZhengAs an overseas high-level talent in Beijing and a specially appointed expert. His educational background includes a bachelor's degree from Lanzhou University, a master's degree from Peking Union Medical College, and a Ph.D. from the University of Alberta in Canada. He also completed his postdoctoral training at the University of Toronto under the tutelage of a world-renownedCanadian cancerologist Tony Pawson, AcademicianFormerly served as an assistant researcher at the LTRI Institute of Mount Sinai Hospital and as a professor and doctoral supervisor at the National Center for Protein Science (Beijing). Published a landmark article on proteomics in Nature magazine and received support from multiple research funds, including the National Key R&D Program of China and the National Natural Science Foundation of China.

Co-founder, Chief Scientist Dr. Zheng DexianForProfessor, School of Basic Medicine, Peking Union Medical College, an expert receiving special subsidy from the State Council. His education and work experience include undergraduate at Peking University, joint Ph.D. training program by the U.S. NIH\China CMMS, postdoctoral fellowship at the U.S. FDA, guest professor at Harvard Medical School, former dean of the Institute of Basic Medical Sciences at Peking Union Medical College, director and academic committee chair of the State Key Laboratory of Experimental Hematology, vice president of the Chinese Society for Immunology, executive council member of the International Union of Immunological Societies, etc. He has led numerous "863", "973", and major national new drug creation projects. He served as the chief scientist and R&D president of OBiO Technology. He has successively led the R&D of three new drug INDs, and obtained 15 patents approved both domestically and internationally.

The company has a multidisciplinary core team. Members not only have backgrounds from top research institutions such as Harvard University, the University of Toronto, the Wharton School, Tsinghua University, Peking University, Peking Union Medical College, the National Center for Protein Science, and the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences, but also possess executive experience from leading pharmaceutical companies like Pfizer, Takeda, Fosun Pharma, as well as renowned technology companies such as Apple, Tencent Healthcare, and Alibaba Health. The company has world-class capabilities in the fields of proteomics, antibody drugs, and AI computing.